
What is claimed is:

1. A compound having formula (I):



I

or a pharmaceutically acceptable salt, solvate, clathrate or hydrate thereof, wherein

X is O or $S(O)_t$;

R^a is O or S;

each R^1 is independently selected from (i) or (ii) below:

i) each R^1 is independently selected from a group consisting of halo, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, $—R^6OR^7$, $—R^6SR^7$, $—R^6S(O)_tR^8$, $—R^6N(R^7)_2$, $—R^6OR^9OR^7$, $—R^6OR^9SR^7$, $—R^6OR^9S(O)_tR^8$, $—R^6OR^9S(O)_tN(R^7)_2$, $—R^6OR^9N(R^7)_2$, $—R^6SR^9OR^7$, $—R^6SR^9SR^7$, $—R^6SR^9N(R^7)_2$, $—R^6N(R^7)R^9N(R^7)_2$, $—R^6N(R^7)R^9OR^7$, $—R^6N(R^7)R^9SR^7$, $—R^6CN$, $—R^6C(O)R^7$, $—R^6C(O)OR^7$, $—R^6C(O)OR^9OR^7$, $—R^6C(O)N(R^7)_2$, $—R^6C(O)N(R^7)OR^7$, $—R^6C(NR^7)N(R^7)_2$, $—R^6C(O)N(R^7)R^9N(R^7)_2$, $—R^6C(O)N(R^7)R^9OR^7$, $—R^6C(O)N(R^7)R^9SR^7$, $—R^6C(O)SR^8$, $—R^6S(O)_tOR^7$, $—R^6S(O)_tN(R^7)_2$, $—R^6S(O)_tN(R^7)N(R^7)_2$, $—R^6S(O)_tN(R^7)$

$N{=}C(R^7)_2$, $-R^6S(O)_tN(R^7)C(O)R^8$, $-R^6S(O)_tN(R^7)C(O)N(R^7)_2$, $-R^6S(O)_tN(R^7)C(NR^7)N(R^7)_2$, $-R^6N(R^7)C(O)R^8$, $-R^6N(R^7)C(O)OR^8$, $-R^6N(R^7)C(O)N(R^7)_2$, $-R^6N(R^7)C(NR^7)N(R^7)_2$, $-R^6N(R^7)C(S)N(R^7)_2$, and $-R^6N(R^7)S(O)_tR^8$, or

ii) any two adjacent R^1 groups together form an alkylenedioxy group;

each R^6 is independently a direct bond, alkylene chain or alkenylene chain;

each R^7 is independently selected from (i) or (ii) below:

(i) each R^7 is selected from a group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaralkyl, or

(ii) two R^7 groups together with the N atom to which they are attached form a heterocyclyl or heteroaryl;

each R^8 is independently selected from a group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaralkyl;

each R^9 is independently an alkylene chain or an alkenylene chain;

R^2 is hydrogen, halo, alkyl, amino or alkylamino;

R^3 is halo or alkyl;

R^4 and R^5 are selected as follows:

a) R^4 and R^5 are each independently hydrogen or alkyl, or

b) R^4 and R^5, together with the N atom to which they are attached, form an oxo-substituted heterocyclyl;

R^{11} is isoxazolyl;

m is an integer from 0 to 4;

n is an integer from 0 to 4;

t is an integer from 0 to 2;

R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9 and R^{11} are optionally substituted with one, two or three substituents independently selected from Q^1, wherein Q^1 is nitro, halo, azido, cyano, oxo, thioxo, imino, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, $—R^uOR^x$, $—R^uOR^uOR^x$, $—R^uOR^uN(R^y)(R^z)$, $—R^u N(R^y)(R^z)$, $—R^uSR^x$, $—R^uC(J)R^x$, $—R^uC(J)OR^x$, $—R^uC(J)N(R^y)(R^z)$, $—R^uC(J)SR^x$, $—R^uS(O)_tR^w$, $—R^uOC(J)R^x$, $—R^uOC(J)OR^x$, $—R^uOC(J)N(R^y)(R^z)$, $—R^uOC(J)SR^x$, $—R^uN(R^x)C(J)R^x$, $—R^uN(R^x)C(J)OR^x$, $—R^uN(R^x)C(J)N(R^y)(R^z)$, $—R^uN(R^x)C(J)SR^x$, $—R^uSi(R^w)_3$, $—R^uN(R^x)S(O)_tR^w$, $—R^uN(R^x)R^uS(O)_2R^w$, $—R^uN(R^x)S(O)_2N(R^y)(R^z)$, $—R^uS(O)_2N(R^y)(R^z)$, $—R^uP(O)(R^v)_2$, $—R^uOP(O)(R^v)_2$, $—R^uC(J)N(R^x)S(O)_2R^v$, $—R^uC(J)N(R^x)N(R^x)S(O)_2R^w$, $—R^uC(R^x)=N(OR^x)$ or $—R^uC(R^x)=NN(R^y)(R^z)$;

when Q^1 is alkyl, alkenyl or alkynyl, each Q^1 is optionally substituted with halo, cyano, hydroxy or alkoxy;

when Q^1 is cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl, each Q^1 is optionally substituted with halo, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cyanoalkyl, alkoxy or hydroxyl;

each R^u is independently alkylene or a direct bond;

each R^v is independently alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydroxy, $—OR^x$ or $—N(R^y)(R^z)$;

R^w is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl;


each R^x is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl;

R^y and R^z are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl;

R^y and R^z, together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl; and

J is O, NR^x or S.

2. The compound of claim **1** having formula (II):



II

or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein

X is O, S, S(O) or SO_2;

each R^1 is independently selected from (i) or (ii) below:

i) each R^1 is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, $—R^6OR^7$, $—R^6SR^7$, $—R^6S(O)_tR^8$, $—R^6N(R^7)_2$, $—R^6OR^9OR^7$, $—R^6OR^9SR^7$, $—R^6OR^9S(O)_tR^8$, $—R^6OR^9S(O)_tN(R^7)_2$, $—R^6OR^9N(R^7)_2$, $—R^6SR^9OR^7$, $—R^6SR^9SR^7$,

—$R^6SR^9N(R^7)_2$, —$R^6N(R^7)R^9N(R^7)_2$, —$R^6N(R^7)R^9OR^7$, —$R^6N(R^7)R^9SR^7$, —R^6CN, —$R^6C(O)R^7$, —$R^6C(O)OR^7$, —$R^6C(O)OR^9OR^7$, —$R^6C(O)N(R^7)_2$, —$R^6C(O)N(R^7)OR^7$, —$R^6C(O)N(R^7)R^9OR^7$, —$R^6C(O)N(R^7)R^9SR^7$, —$R^6C(O)SR^8$, —$R^6S(O)_tOR^7$, and —$R^6S(O)_tN(R^7)_2$; or

ii) any two adjacent R^1 groups together form an alkylenedioxy group;

each R^6 is independently a direct bond, alkylene chain or alkenylene chain;

each R^7 is independently selected from (i) or (ii) below:

(i) each R^7 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaralkyl, or

(ii) two R^7 groups together with the N atom to which they are attached form a heterocyclyl or heteroaryl;

each R^9 is independently an alkylene chain or an alkenylene chain;

R^3 is halo or alkyl;

R^4 and R^5 are each independently hydrogen or alkyl;

R^{11} is isoxazolyl;

m is an integer from 0 to 4;

n is an integer from 0 to 4,

R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9 and R^{11} are optionally substituted with one, two or three substituents independently selected from Q^1, wherein Q^1 is nitro, halo, azido, cyano, oxo, thioxo, imino, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl, —R^uOR^x, —$R^uOR^uOR^x$, —$R^uOR^uN(R^y)(R^z)$, —$R^uN(R^y)(R^z)$, —R^uSR^x, —$R^uC(J)R^x$, —$R^uC(J)OR^x$, —$R^uC(J)N(R^y)(R^z)$, —$R^uC(J)SR^x$, —$R^uS(O)_tR^w$, —$R^uOC(J)R^x$, —$R^uOC(J)OR^x$, —$R^uOC(J)N(R^y)(R^z)$, —$R^uOC(J)SR^x$, —$R^uN(R^x)C(J)R^x$, —$R^uN(R^x)C(J)OR^x$, —$R^uN(R^x)C$

(J)N(R^y)(R^z), —R^uN(R^x)C(J)SR^x, —R^uSi(R^w)$_3$, —R^uN(R^x)S(O)$_2$$R^w$, —$R^u$N($R^x$)$R^u$S(O)$_2$$R^w$, —$R^u$N($R^x$)S(O)$_2$N($R^y$)($R^z$), —$R^u$S(O)$_2$N($R^y$)($R^z$), —$R^u$P(O)($R^v$)$_2$, —$R^u$OP(O)($R^v$)$_2$, —$R^u$C(J)N($R^x$)S(O)$_2$$R^w$, —$R^u$C(J)N($R^x$)N($R^x$)S(O)$_2$$R^w$, —$R^u$C($R^x$)=N(O$R^x$) or —$R^u$C($R^x$)=NN($R^y$)($R^z$);

when Q^1 is alkyl, alkenyl or alkynyl, each Q^1 is optionally substituted with halo, cyano, hydroxy or alkoxy;

when Q^1 is cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl, each Q^1 is optionally substituted with halo, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cyanoalkyl, alkoxy, hydroxyl, oxo or cyano;

each R^u is independently alkylene or a direct bond;

each R^v is independently alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydroxy, —OR^x or —N(R^y)(R^z),

R^w is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl;

each R^x is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl;

R^y and R^z are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl;

R^y and R^z, together with the nitrogen atom to which they are attached, form a heterocycle or heteroaryl;

t is an integer from 0 to 2; and

J is O, NR^x or S.

3. The compound of claim 1, wherein the compound is a pharmaceutically acceptable salt of the compound of formula (I).

4. The compound of claim 1, wherein the compound is a solvate of the compound of formula (I).


5. The compound of claim 1, wherein the compound is a hydrate of the compound of formula (I).

6. The compound of claim 1, wherein X is O or S.

7. The compound of claim 1, wherein R^3 is methyl, chloro or fluoro.

8. The compound of claim 1, wherein the compound has formula III:


III



or a pharmaceutically acceptable salt, solvate or hydrate thereof.


9. The compound of claim 1, wherein the compound has formula IV:


IV




or a pharmaceutically acceptable salt, solvate or hydrate thereof.

10. The compound of claim **1**, wherein R^{11} is selected from the group consisting of:






and




and each R^{10} is independently selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, alkoxyalkoxy, aryl, heterocyclyl, heterocyclylcarbonyl, alkoxycarbonyl and heteroaryl, where the alkyl, aryl, heteroaryl and heterocyclyl groups are optionally substituted with 1 to 5 groups selected from halo, cyano, hydroxy, alkoxy, cycloalkyl, heterocyclyl, alkylcarbonyl and alkoxycarbonyl.

11. The compound of claim **1**, wherein R^{11} is



where R^{10} is hydrogen, alkyl, hydroxyalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, alkoxyalkyl, aryl or heteroaryl.

12. The compound of claim **1**, wherein R^{11} is



13. The compound of claim **1**, wherein each R^1 is selected as follows:

i) each R^1 is independently selected from the group consisting of hydrogen, halo, nitro, amino, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, $—R^6OR^7$, $—R^6SR^7$, $—R^6N(R^7)_2$, $—R^6OR^9OR^7$, $—R^6OR^9SR^7$, $—R^6SR^9OR^7$, $—R^6SR^9SR^7$, $—R^6OR^9N(R^7)_2$, $—R^6SR^9N(R^7)_2$, $—R^6CN$, $—R^6C(O)R^7$, $—R^6C(O)OR^7$, $—R^6C(O)OR^9OR^7$, $—R^6C(O)N(R^7)_2$ and $—R^6N(R^7)C(O)R^8$; or

ii) any two adjacent R^1 groups together form an alkylenedioxy group;

each R^6 is independently a direct bond, alkylene chain or alkenylene chain;

each R^7 is independently selected from (i) or (ii) below:

(i) each R^7 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaralkyl, or


(ii) two R^7 groups together with the N atom to which they are attached form a heterocyclyl or heteroaryl;

each R^9 is independently an alkylene chain or an alkenylene chain,

wherein R^1, R^6, R^7 and R^9 groups are optionally substituted with one, two or three Q^1 groups, wherein each Q^1 is independently haloalkyl, alkyl, $—R^uOR^x$, $—R^uC(J)OR^x$, $—R^uS(O)_2R^w$, $—R^uN(R^x)S(O)_2R^w$ or $—R^uN(R^x)R^uS(O)_2R^w$, wherein R^u is direct bond or alkylene, R^x is hydrogen or alkyl; R^w is alkyl and J is O, S or NR^x, such that at least one R^1 is other than hydrogen.

14. The compound of claim **1** having formula XII:

XII




or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R^a is O or S;

X is O or S;

R^{1a} and R^{1b} are selected as follows:

i) R^{1a} and R^{1b} are each independently selected from hydrogen, halo, amino, alkyl, aryl, heteroaryl, alkoxy, hydroxy, alkoxyalkoxy, cycloalkylcarbonylamino and a group of formula:



where each K is independently a direct bond or alkylene;

A is N or CR^{16};

Y is —O, —S, —S(O), —$S(O)_2$, —$N(R^{14})$, —$C(H)R^{15}$, or —C(O);

p is an integer from 0 to 2;

R^{14} is hydrogen, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, heteroarylalkyl, arylalkyl, $S(O)_tR^{13}$ or —$C(O)R^{12}$;

R^{15} is hydrogen, halo, alkyl, hydroxyalkyl or —OR^{12};

R^{16} is hydrogen or alkyl;

t is 1 or 2;

each R^{12} is independently selected from the group consisting of hydrogen and alkyl;


R^{13} is alkyl;

each K is optionally substituted with one, two or three hydroxy or alkyl groups; or

ii) R^{1a} and R^{1b} groups together form an alkylenedioxy group.

15. The compound of claim **1** having formula XVII:

XVII




or a pharmaceutically acceptable salt, solvate or hydrate thereof,

wherein X is O or S;

R^{1a} and R^{1b} are selected as follows:

i) R^{1a} and R^{1b} are each independently alkoxy, alkoxy-alkoxy, alkylsulfonylalkoxy or a group of formula:



where K is a direct bond or alkylene, optionally substituted with a hydroxy group;


A is N or CH;

Y is —O, —$S(O)_2$, —$N(R^{14})$ or —$C(H)R^{15}$;

p is 0 or 1;
R^{14} is hydrogen, alkyl, haloalkyl, hydroxyalkyl or $S(O)_t$ R^{13};
R^{15} is hydrogen, halo, alkyl, hydroxyalkyl or —OR^{12};
t is 1 or 2;
R^{12} is hydrogen or alkyl; and
R^{13} is alkyl; or
ii) R^{1a} and R^{1b} groups together form an alkylenedioxy group; and
R^{10} is hydrogen, halo, alkyl, aryl, heterocyclyl, heteroaryl, cycloalkyl or cycloalkylalkyl; where alkyl, aryl, heterocyclyl and heteroaryl groups are optionally substituted with 1-3 groups selected from halo, cyano, hydroxyl and alkoxy.


16. The compound of claim **1** having formula XIX:

XIX



or a pharmaceutically acceptable salt, solvate or hydrate thereof,
wherein X is O or S;
R^{1a} and R^{1b} are selected as follows:

i) R^{1a} and R^{1b} are each independently methoxy, methoxyethoxy, methylsulfonylpropyloxy, or a group of formula:



where K is ethylene or propylene, optionally substituted with a hydroxy group;

A is N or CH;

Y is —O, —$S(O)_2$, —$N(R^{14})$ or —$C(H)R^{15}$;

p is 1;

R^{14} is hydrogen, methyl, hydroxyethyl, or methylsulfonyl;

R^{15} is hydrogen, hydroxymethyl, hydroxyethyl or hydroxy; or

ii) R^{1a} and R^{1b} groups together with the carbon atoms on which they are substituted form an ethylenedioxy group; and

R^{10} is hydrogen, halo, alkyl, aryl, heterocyclyl, heteroaryl, cycloalkyl or cycloalkylalkyl; where alkyl, aryl, heterocyclyl and heteroaryl groups are optionally substituted with 1-3 groups selected from halo, cyano, hydroxyl and alkoxy.

17. The compound of claim **1** selected from

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxyquinazolin-4-yloxyphenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxyquinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6,7-difluoroquinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(5-methylquinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-[3-(7-ethoxy-6-methoxyquinazolin-4-yloxy)phenyl]urea hydrochloride;
1-(5-tert-Butylisoxazol-3-yl)-3-{3-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy]phenyl}urea hydrochloride;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methylquinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)-4-fluorophenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(4-chloro-3-(6,7-dimethoxyquinazolin-4-yl oxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-ethoxy-7-methoxyquinazolin-4-yloxy)phenyl)urea;
1-{3-[6,7-bis(2-methoxyethoxy)quinazolin-4-yloxy]phenyl}-3-(5-tert-butylisoxazol-3-yl)urea hydrochloride;
1-(5-tert-Butylisoxazol-3-yl)-3-[3-(6,7-diethoxyquinazolin-4-yloxy)phenyl]urea hydrochloride;
1-(5-tert-Butylisoxazol-3-yl)-3-[3-(7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-yloxy)phenyl]urea hydrochloride;
1-(5-tert-butylisoxazol-3-yl)-3-{3-[7-methoxy-6-(2-methoxyethoxy)quinazolin-4-yloxy]phenyl}urea hydrochloride;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(2-(piperidin-1-yl)ethoxy)quinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(2-(4-(hydroxymethyl)piperidin-1-yl)ethoxy)-7-methoxyquinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(2-(4-methylpiperazin-1-yl)ethoxy)quinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(2-(4-(2-hydroxyethyl)piperazin-1-yl)ethoxy)-7-methoxyquinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(2-morpholinoethoxy)quinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(3-(4-methyl piperazin-1-yl)propoxy)quinazolin-4-yloxy) phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(3-(piperidin-1-yl)propoxy)quinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(3-(4-(hydroxymethyl)piperidin-1-yl)propoxy)-7-methoxyquinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(3-(4-(methylsulfonyl)piperazin-1-yl)propoxy)quinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butyl-isoxazol-3-yl)-3-(3-{6-[3-(1,1-dioxo-thiomorpholin-4-yl)-propoxy]-7-methoxy-quinazolin-4-yloxy}-phenyl)-urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yloxy) phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-(3-(4-hydroxymethyl)piperidin-1-yl)propoxy)-6-methoxyquinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propoxy)-6-methoxyquinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butyl-isoxazol-3-yl)-3-(3-{7-[3-(3-hydroxy-pyrrolidin-1-yl)-propoxy]-6-methoxy-quinazolin-4-yloxy}-phenyl)-urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(3-(4-(methyl sulfonyl)piperazin-1-yl)propoxy)quinazolin-4-yloxy)phenyl)urea;

(S)-1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-(3-(3-hydroxypyrrolidin-1-yl)propoxy)-6-methoxyquinazolin-4-yloxy)phenyl)urea;

(R)-1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-(3-(3-hydroxypyrrolidin-1-yl)propoxy)-6-methoxyquinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-morpholinoethoxy)quinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-(4-methyl piperazin-1-yl)ethoxy)quinazolin-4-yloxy)phenyl)urea;

1-(5-tert-Butyl-isoxazol-3-yl)-3-(3-{7-[2-(4-hydroxymethyl-piperidin-1-yl)-ethoxy]-6-methoxy-quinazolin-4-yloxy}-phenyl)-urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-(2-(4-(2-hydroxyethyl)piperazin-1-yl)ethoxy)-6methoxyquinazolin-4-yloxy)phenyl)urea;

1-(5-tert-Butyl-isoxazol-3-yl)-3-(3-{7-[2-(1,1-dioxo-116-thiomorpholin-4-yl)-ethoxy]-6-methoxy-quinazolin-4-yloxy}-phenyl)-urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea

1-(5-tert-Butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(3-(methylsulfonyl)propoxy)quinazolin-4-ylthio)phenyl)urea;

1-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)-3-(3-(7-methoxy-6-(3-(methylsulfonyl)propoxy)quinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-(2-methoxyethoxy) quinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(3-(methylsulfonyl)propoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(2-methoxyethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6,7-difluoroquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxyquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxyquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-Butylisoxazol-3-yl)-3-[3-(7-ethoxy-6-methoxyquinazolin-4-ylthio)phenyl]urea;
1-(5-tert-butylisoxazol-3-yl)-3-[3-(6,7-diethoxyquinazolin-4-ylthio)phenyl]urea;
1-(5-tert-butylisoxazol-3-yl)-3-{3-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-ylthio]phenyl}urea hydrochloride;
1-{3-[6,7-bis(2-methoxyethoxy)quinazolin-4-ylthio]phenyl}-3-(5-tert-butylisoxazol-3-yl)urea hydrochloride;
1-(5-tert-butylisoxazol-3-yl)-3-[3-(7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-ylthio) phenyl]urea hydrochloride;
1-(5-tert-Butylisoxazol-3-yl)-3-{3-[7-methoxy-5-(tetrahydro-2H-pyran-4-ylthio)quinazolin-4-yloxy] phenyl}urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-ethoxy-7-methoxyquinazolin-4-ylthio)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(3-(piperidin-1-yl)propoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(3-(4-(hydroxymethyl)piperidin-1-yl)propoxy)-7-methoxyquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-Butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(3-(4-methylpiperazin-1-yl)propoxy) quinazolin-4-ylthio) phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(3-(4-(methylsulfonyl)piperazin-1-yl)propoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propoxy)-7-methoxyquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butyl-isoxazol-3-yl)-3-(3-{6-[3-(1,1-dioxo-thiomorpholin-4-yl)-propoxy]-7-methoxy-quinazolin-4-yl-sulfanyl}-phenyl)-urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(3-(methylsulfonyl)propoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(2-(piperidin-1-yl)ethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(2-(4-(hydroxymethyl)piperidin-1-yl)ethoxy)-7-methoxyquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(2-(4-methylpiperazin-1-yl)ethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(2-(4-(2-hydroxyethyl)piperazin-1-yl)ethoxy)-7-methoxyquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(2-(4-(methylsulfonyl)piperazin-1-yl)ethoxy)quinazolin-4-ylthio)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(2-morpholinoethoxy)quinazolin-4-ylthio)phenyl)urea;

1-(5-tert-butyl-isoxazol-3-yl)-3-(3-{6-[2-(1,1-dioxo-thiomorpholin-4-yl)-ethoxy]-7-methoxy-quinazolin-4-ylsulfanyl}-phenyl)-urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-morpholinoethoxy)quinazolin-4-ylthio)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-ylthio)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-(3-(4-(hydroxylmethyl)piperidin-1-yl)propoxy)-6-methoxyquinazolin-4-ylthio)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propoxy)-6-methoxyquinazolin-4-ylthio)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-ylthio)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(3-(4-(methylsulfonyl)piperazin-1-yl)propoxy)quinazolin-4-ylthio)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-morpholinoethoxy)quinazolin-4-ylthio)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-(piperidin-1-yl)ethoxy)quinazolin-4-ylthio)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-(4-(methylsulfonyl)piperazin-1-yl)ethoxy)quinazolin-4-ylthio)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazolin-4-ylthio)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-(2-(4-(2-hydroxyethyl)piperazin-1-yl)ethoxy)-6-methoxyquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-(2-(4-(hydroxymethyl)piperidin-1-yl)ethoxy)-6-methoxyquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(2-methoxyethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(2-(methylsulfonyl)ethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(2-chloro-6,7-dimethoxyquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-Butyl-isoxazol-3-yl)-3-(3-{6-[3-(1,1-dioxo-thiomorpholin-4-yl)-propoxy]-quinazolin-4-ylsulfanyl}-phenyl)-urea;
1-(5-tert-Butyl-isoxazol-3-yl)-3-(3-{6-[2-(1,1-dioxo-116-thiomorpholin-4-yl)-ethoxy]-7-methoxy-quinazolin-4-yloxy}-phenyl)-urea;
1-(5-tert-butylisoxazol-3-yl)-3-{3-[6-(5-{[2-(methylsulfonyl)ethylamino]methyl}furan-2-yl)quinazolin-4-yloxy]phenyl}urea;
1-(5-tert-butylisoxazol-3-yl)-3-{3-[7-methoxy-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-yloxy]phenyl}urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-hydroxy-6-methoxyquinazolin-4-yloxy)phenyl)urea;
(S)-1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(pyrrolidin-3-yloxy)quinazolin-4-yloxy)phenyl)urea;
(S)-1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(1-methylpyrrolidin-3-yloxy)quinazolin-4-yloxy)phenyl);
urea mono acetate;
(R)-1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(pyrrolidin-3-yloxy)quinazolin-4-yloxy)phenyl)urea;
(R)-1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(1-methylpyrrolidin-3-yloxy)quinazolin-4-yloxy)phenyl)urea mono acetate;

(R)-1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-(2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy)-6-methoxyquinazolin-4-yloxy)phenyl)urea;

1-(3-tert-Butylisoxazol-5-yl)-3-(3-(6-methoxy-7-(piperidin-4-ylmethoxy)quinazolin-4-yloxy)phenyl)urea;

1-(3-tert-butylisoxazol-5-yl)-3-(3-(6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-yloxy)phenyl)urea;

(S)-1-(5-tert-butylisoxazol-3-yl)-3-(3-{7-[1-(2,2-difluoroethyl)pyrrolidin-3-yloxy]-6-methoxyquinazolin-4-yloxy}phenyl)urea;

(S)-1-(5-tert-Butylisoxazol-3-yl)-3-(3-{6-methoxy-7-[1-(2,2,2-trifluoroethyl)pyrrolidin-3-yloxy]quinazolin-4-yloxy}phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-{7-[1-(2,2-difluoroethyl)piperidin-4-yloxy]-6-methoxyquinazolin-4-yloxy}phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-hydroxy-7-methoxyquinazolin-4-yloxy)phenyl)urea;

(S)-tert-butyl 3-(4-(3-(3-(5-tert-butylisoxazole-3-yl)ureido)phenoxy)-7-methoxyquinazolin-6-yloxy)pyrrolidine-1-carboxylate;

(S)-1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(1-methylpyrrolidin-3-yloxy)quinazolin-4-yloxy)phenyl)urea;

(S)-1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(1-(2,2-difluoroethyl)pyrrolidin-3-yloxy)-7-methoxyquinazolin-4-yloxy)phenyl)urea;

(S)-1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy)-7-methoxyquinazolin-4-yloxy)phenyl)urea;

(R)-1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy)-7-methoxyquinazolin-4-yloxy)phenyl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-phenylisoxazol-3-yl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-isopropylisoxazol-5-yl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(tetrahydro-2H-pyran-4-yl)isoxazol-5-yl)urea;

1-(3-cyclopropylisoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea;

1-(3-(2-cyanopropan-2-yl)isoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1-methylcyclopropyl)isoxazol-3-yl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1-hydroxy-2-methylpropan-2-yl)isoxazol-3-yl)urea;

1-(3-tert-butylisoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-isopropylisoxazol-3-yl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl)-3-(5-isopropylisoxazol-3-yl)urea;

1-(5-cyclopentylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(2-fluoropropan-2-yl)isoxazol-3-yl)urea;

1-(3-(1,1-difluoroethyl)isoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(1-(trifluoromethyl)cyclobutyl)isoxazol-5-yl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl)-3-(3-(1-(trifluoromethyl)cyclobutyl)isoxazol-5-yl)urea;

1-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl)urea;
1-[3-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-5-yl]-3-[3-(6,7-dimethoxyquinazolin-4-yloxy]phenyl)urea;
1-[3-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-5-yl]-3-[3-(6,7-dimethoxyquinazolin-4-ylthio]phenyl)urea;
1-[5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl]-3-[3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl]urea;
1-(3-cyclopentylisoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea;
1-(3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;
1-[5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl]-3-[3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl]urea;
1-(5-cyclopentylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl)urea;
1-(3-tert-butylisoxazol-5-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;
1-(3-(6-Methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)-3-(5-phenylisoxazol-3-yl)urea;
1-(5-isopropylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;
1-(3-cyclopentylisoxazol-5-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;
1-(3-(1,1-difluoroethyl)isoxazol-5-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;
1-[5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl]-3-{3-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy]phenyl}urea;
1-(3-cyclopropylisoxazol-5-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;

1-(3-isopropylisoxazol-5-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;
1-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)-3-(3-(tetrahydro-2H-pyran-4-yl)isoxazol-5-yl)urea;
1-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;
1-(5-cyclopentylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;
1-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)-3-(3-(trifluoromethyl)isoxazol-5-yl)urea;
1-[5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl]-3-{3-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-ylthio]phenyl}urea;
1-(5-isopropylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-cyclopentylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)-3-(3-(7-methoxy-6-(4,4-dioxo-3-thiomorpholinopropoxy)quinazolin-4-ylthio)phenyl)urea;
1-(3-(6,7-bis(2-Methoxyethoxy)quinazolin-4-ylthio)phenyl)-3-(3-tert-butylisoxazol-5-yl)urea;
1-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)-3-(3-(6-methoxy-7-(2-morpholinoethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)-3-(3-(6-methoxy-7-(2-morpholinoethoxy)quinazolin-4-yloxy)phenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-ylsulfinyl)phenyl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(trifluoromethyl)isoxazol-5-yl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)urea;

1-(5-tert-butyl-isoxazol-3-yl)-3-(3-{7-[3-(1,1-dioxo-thiomorpholin-4-yl)-propoxy]-6-methoxy-quinazolin-4-yloxy}-phenyl)-urea;

1-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)-3-(3-(7-hydroxy-6-methoxyquinazolin-4-yloxy)phenyl)urea;

1-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)-3-(3-(6-hydroxy-7-methoxyquinazolin-4-yloxy)phenyl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;

1-(3-(6-ethoxy-7-methoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;

1-(3-(6-ethoxy-7-methoxyquinazolin-4-ylthio)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;

1-(3-(7-hydroxy-6-methoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;

1-(3-(6-hydroxy-7-methoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)-2-fluorophenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)-4-fluorophenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-5-yl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl)-3-(3-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-5-yl)urea; and

1-(5-(6,7-dimethoxyquinazolin-4-yloxy)-2,4-difluorophenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl) urea,

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

18. The compound of claim **1** selected from

1-(5-tert-butylisoxazol-3-yl)-3-(5-(6,7-dimethoxyquinazolin-4-yloxy)-2,4-difluorophenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)-2-methylphenyl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)-2-methylphenyl)-3-(5-(2-fluoropropan-2-yl)isoxazol-3-yl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)-4-fluorophenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;

1-(5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)-4-fluorophenyl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)-2-fluorophenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;

1-(5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)-2-fluorophenyl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(2-chloro-5-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea;

1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(2-methyl-1-morpholinopropan-2-yl)isoxazol-3-yl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(3-(2-chloro-6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(5-(6,7-dimethoxyquinazolin-4-yloxy)-2-fluorophenyl)urea;
1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1-(trifluoromethyl)cyclopropyl)isoxazol-3-yl)urea;
1-(3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl)-3-(5-(1-(trifluoromethyl)cyclopropyl)isoxazol-3-yl)urea;
1-(3-(2-cyanopropan-2-yl)isoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl)urea;
1-(3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl)-3-(3-(trifluoromethyl)isoxazol-5-yl)urea;
1-(3-(7-ethoxy-6-methoxyquinazolin-4-yloxy)phenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;
1-(5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl)-3-(3-(7-ethoxy-6-methoxyquinazolin-4-yloxy)phenyl) urea;
1-(5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl)-3-(3-(7-ethoxy-6-methoxyquinazolin-4-ylthio)phenyl) urea;
1-(3-(7-ethoxy-6-methoxyquinazolin-4-ylthio)phenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;
1-(3-(6-ethoxy-7-methoxyquinazolin-4-yloxy)phenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;
1-(5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl)-3-(3-(6-ethoxy-7-methoxyquinazolin-4-yloxy)phenyl) urea;
1-(3-(6-ethoxy-7-methoxyquinazolin-4-ylthio)phenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;
or a pharmaceutically acceptable salt, solvate or hydrate thereof.

19. A composition comprising the compound of claim **1** and a pharmaceutically acceptable carrier, excipient or diluent.

20. The composition of claim **19** further comprising a second therapeutic agent selected from a chemotherapeutic agent, an anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory agent or an immunosuppressive agent.

21. A method of treating a cancer in a patient a therapeutically effective amount of the compound of claim **1** wherein the cancer is melanoma, thyroid carcinoma, colorectal, ovarian, breast cancer, endometrial cancer, liver cancer, sarcoma, stomach cancer, Barret's adenocarcinoma, glioma, small cell lung cancer, non-small cell lung cancer, head and neck cancer, acute lymphoblastic leukemia or non-Hodgkin's lymphoma.

22. A method of treating an inflammatory disease in a patient comprising administrating to the patient a therapeutically effective amount of the compound of claim **1** wherein the inflammatory disease is immune dysfunction, immunodeficiency, immunomodulation, autoimmune disease, tissue transplant rejection, graft-versus-host disease, wound healing, kidney disease, multiple sclerosis, thyroiditis, type 1 diabetes, sarcoidosis, allergic rhinitis, inflammatory bowel

disease, systemic lupus erythematosis, arthritis, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma or chronic obstructive pulmonary disease.

23. The method of claim **21** further comprising administering a second therapeutic agent selected from a chemotherapeutic agent, an anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory agent or an immunosuppressive agent.


24. The method of claim **23**, wherein the second therapeutic agent is selected from an anti-metabolite, a topoisomerase inhibitor and platinum agent.

25. The method of claim **23**, wherein the second therapeutic agent is selected from 5-fluoro-uracil, methotrexate, fludarabine, vincristine, vinblastine, paclitaxel, docetaxel, cyclophosphamide, melphalan, carmustine, bischloroethylnitrosurea, hydroxyurea, cisplatin, carboplatin, oxaliplatin, satraplatin, CI-973, doxorubicin, daunorubicin, mitomycin, idarubicin, adriamycin, daunomycin, etoposide, camptothecins, sorafenib, bevacizumab, estramustine phosphate and prednimustine.


26. The method of claim **21**, wherein the cancer is papillary thyroid carcinoma.

What is claimed is:

1. A compound having formula VA or VB:



VA



VB

or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein
r is 0, 1 or 2;
X is O or S;
n is 1 to 4
R^a is O;
R^4 and R^5 are each independently hydrogen or methyl;
R^{10} is independently selected from halo, haloalkyl, alkyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl where the alkyl group is optionally substituted with 1 or 2 groups selected from halo and cyano, and where the cycloalkyl, aryl and heteroaryl group is optionally substituted with 1 or 2 groups selected from halo, cyano, alkyl and haloalkyl; and
each R^1 is absent, or is independently selected from
halo, nitro, alkyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl, heteroaryl, heteroaralkyl, cycloalkylcarbonylamino, $—R^6OR^7$, $—R^6OR^9OR^7$, $—R^6OR^9N(R^7)_2$, or
any two adjacent R^1 groups together form an alkylenedioxy group;
each R^6 is independently a direct bond, alkylene chain or alkenylene chain;
each R^7 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaralkyl, or
two R^7 groups together with the N atom to which they are attached form a heterocyclyl or heteroaryl; or
each R^9 is independently an alkylene chain or an alkenylene chain.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^4 and R^5 are each hydrogen.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R^1 is selected from the group consisting of $—R^6OR^7$, $—R^6OR^9OR^7$, $—R^6OR^9N(R^7)_2$; and

each R^6 is independently a direct bond, alkylene chain or alkenylene chain;


each R^7 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaralkyl, or

two R^7 groups together with the N atom to which they are attached form a heterocyclyl or heteroaryl; and

each R^9 is independently an alkylene chain or an alkenylene chain.

4. The compound of claim 1 having formula XVII:

XVII



or a pharmaceutically acceptable salt, solvate or hydrate thereof,

wherein X is O or S;


R^{1a} and R^{1b} are independently selected from alkoxy, alkoxyalkoxy, or alkylsulfonylalkoxy; or

two R^{1a} and R^{1b} groups together form an alkylenedioxy group; and

R^{10} is hydrogen, halo, alkyl, haloalkyl, aryl, heterocyclyl, heteroaryl, cycloalkyl or cycloalkylalkyl.

5. The compound of claim 1 having formula XIX:

XIX



or a pharmaceutically acceptable salt, solvate or hydrate thereof,

wherein X is O or S;

R^{1a} and R^{1b} are independently selected from methoxy, methoxyethoxy, or methylsulfonylpropyloxy; or

two R^{1a} and R^{1b} groups together with the carbon atoms on which they are substituted form an ethylenedioxy group; and

oo

R^{10} is hydrogen, halo, alkyl, haloalkyl, aryl, heterocyclyl, heteroaryl, cycloalkyl or cycloalkylalkyl.

6. The compound selected from
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxyquinazolin-4-yloxyphenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxyquinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6,7-difluoroquinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(5-methylquinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-[3-(7-ethoxy-6-methoxyquinazolin-4-yloxy)phenyl]urea hydrochloride;
1-(5-tert-butylisoxazol-3-yl)-3-{3-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy]phenyl}urea hydrochloride;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methylquinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)-4-fluorophenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(4-chloro-3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-ethoxy-7-methoxyquinazolin-4-yloxy)phenyl)urea;
1-{3-[6,7-bis(2-methoxyethoxy)quinazolin-4-yloxy]phenyl}-3-(5-tert-butylisoxazol-3-yl)urea hydrochloride;
1-(5-tert-Butylisoxazol-3-yl)-3-[3-(6, 7-diethoxyquinazolin-4-yloxy)phenyl]urea hydrochloride;
1-(5-tert-butylisoxazol-3-yl)-3-[3-(7,8-dihydro-[1,4]dioxino[2,3-g] quinazolin-4-yloxy)phenyl]urea hydrochloride;
1-(5-tert-butylisoxazol-3-yl)-3-{3-[7-methoxy-6-(2-methoxyethoxy)quinazolin-4-yloxy]phenyl}urea hydrochloride;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea
1-(5-tert-Butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(3-(methylsulfonyl)propoxy)quinazolin-4-ylthio)phenyl)urea;
1-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)-3-(3-(7-methoxy-6-(3-(methylsulfonyl)propoxy) quinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(3-(methylsulfonyl)propoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(2-methoxyethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6, 7-dimethoxyquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6, 7-difluoroquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxyquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxyquinazolin-4-ylthio)phenyl)urea;

1-(5-tert-Butylisoxazol-3-yl)-3-[3-(7-ethoxy-6-methoxyquinazolin-4-ylthio)phenyl]urea;
1-(5-tert-butylisoxazol-3-yl)-3-[3-(6, 7-diethoxyquinazolin-4-ylthio)phenyl]urea;
1-(5-tert-butylisoxazol-3-yl)-3-{3-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-ylthio]phenyl}urea hydrochloride;
1-{3-[6,7-bis(2-methoxyethoxy)quinazolin-4-ylthio]phenyl}-3-(5-tert-butylisoxazol-3-yl)urea hydrochloride;
1-(5-tert-butylisoxazol-3-yl)-3-[3-(7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-ylthio) phenyl]urea hydrochloride;
1-(5-tert-butylisoxazol-3-yl)-3-{3-[7-methoxy-5-(tetrahydro-2H-pyran-4-ylthio)quinazolin-4-yloxy]phenyl}urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-ethoxy-7-methoxyquinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(3-(methylsulfonyl)propoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(2-methoxyethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(2-(methylsulfonyl)ethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-{3-[6-(5-{[2-(methylsulfonyl)ethylamino]methyl}furan-2-yl)quinazolin-4-yloxy]phenyl}urea;
1-(5-tert-butylisoxazol-3-yl)-3-{3-[7-methoxy-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-yloxy]phenyl}urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-hydroxy-6-methoxyquinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-hydroxy-7-methoxyquinazolin-4-yloxy)phenyl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-phenylisoxazol-3-yl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-isopropylisoxazo1-5-yl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(tetrahydro-2H-pyran-4-yl)isoxazol-5-yl)urea;
1-(3-cyclopropylisoxazol-5-yl)-3-(3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)urea;
1-(3-(2-cyanopropan-2-yl)isoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1-methylcyclopropyl)isoxazol-3-yl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1-hydroxy-2-methylpropan-2-yl)isoxazol-3-yl)urea;
1-(3-tert-butylisoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-isopropylisoxazo1-3-yl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-ylthio)phenyl)-3-(5-isopropylisoxazo1-3-yl)urea;
1-(5-cyclopentylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(2-fluoropropan-2-yl)isoxazol-3-yl)urea;

1-(3-(1, 1-difluoroethyl)isoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(1-(trifluoromethyl)cyclobutyl)isoxazol-5-yl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-ylthio)phenyl)-3-(3-(1-(trifluoromethyl)cyclobutyl)isoxazol-5-yl)urea;
1-[3-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-5-yl]-3-[3-(6, 7-dimethoxyquinazolin-4-yloxy]phenyl)urea;
1-[3-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-5-yl]-3-[3-(6, 7-dimethoxyquinazolin-4-ylthio]phenyl)urea;
1-[5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl]-3-[3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl]urea;
1-(3-cyclopentylisoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-ylthio)phenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;
1-[5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl]-3-[3-(6, 7-dimethoxyquinazolin-4-ylthio)phenyl]urea;
1-(5-cyclopentylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl)urea;
1-(3-tert-butylisoxazol-5-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;
1-(3-(6-Methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)-3-(5-phenylisoxazol-3-yl)urea;
1-(5-isopropylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;
1-(3-cyclopentylisoxazol-5-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl oxy)phenyl)urea;
1-(3-(1, 1-difluoroethyl)isoxazol-5-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;
1-[5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl]-3-{3-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy]phenyl}urea;
1-(3-cyclopropylisoxazol-5-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl oxy)phenyl)urea;
1-(3-isopropylisoxazol-5-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;
1-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)-3-(3-(tetrahydro-2H-pyran-4-yl)isoxazol-5-yl)urea;
1-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;
1-(5-cyclopentylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)urea;

1-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yloxy)phenyl)-3-(3-(trifluoromethyl)isoxazol-5-yl)urea;
1-[5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl]-3-{3-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-ylthio]phenyl}urea;
1-(5-isopropylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(5-cyclopentylisoxazol-3-yl)-3-(3-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-ylthio)phenyl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(trifluoromethyl)isoxazol-5-yl)urea;
1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)urea;
1-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)-3-(3-(7-hydroxy-6-methoxyquinazolin-4-yloxy)phenyl)urea;
1-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)-3-(3-(6-hydroxy-7-methoxyquinazolin-4-yloxy)phenyl)urea;
1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1, 1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;
1-(3-(6-ethoxy-7-methoxyquinazolin-4-yloxy)phenyl)-3-(5-(1, 1, 1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;
1-(3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl)-3-(5-(1, 1, 1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;
1-(3-(6-ethoxy-7-methoxyquinazolin-4-ylthio)phenyl)-3-(5-(1, 1, 1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;
1-(3-(7-hydroxy-6-methoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1, 1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;
1-(3-(6-hydroxy-7-methoxyquinazolin-4-yloxy)phenyl)-3-(5-(1, 1, 1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;
1-(3-(6,7-dimethoxyquinazolin-4-yloxy)-2-fluorophenyl)-3-(5-(1, 1,1-trifluoro-2-methylpropan-2-yl)isoxazo1-3-yl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)-4-fluorophenyl)-3-(5-(1, 1, 1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(3-(1, 1, 1-trifluoro-2-methylpropan-2-yl)isoxazol-5-yl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-ylthio)phenyl)-3-(3-(1, 1, 1-trifluoro-2-methylpropan-2-yl)isoxazol-5-yl)urea; and
1-(5-(6, 7-dimethoxyquinazolin-4-yl oxy)-2, 4-difluorophenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;

1-(5-tert-butylisoxazol-3-yl)-3-(5-(6, 7-dimethoxyquinazolin-4-yloxy)-2,4-difluorophenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(3-(6, 7-dimethoxyquinazolin-4-yloxy)-2-methylphenyl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)-2-methylphenyl)-3-(5-(2-fluoropropan-2-yl)isoxazol-3-yl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)-4-fluorophenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;
1-(5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl)-3-(3-(6, 7-dimethoxyquinazolin-4-yloxy)-4-fluorophenyl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)-2-fuorophenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;
1-(5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl)-3-(3-(6, 7-dimethoxyquinazolin-4-yloxy)-2-fluorophenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(2-chloro-5-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)urea;
1-(5-tert-butylisoxazol-3-yl)-3-(5-(6,7-dimethoxyquinazolin-4-yloxy)-2-fluorophenyl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1-(trifluoromethyl)cyclopropyl)isoxazol-3-yl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-ylthio)phenyl)-3-(5-(1-(trifluoromethyl)cyclopropyl)isoxazol-3-yl)urea;
1-(3-(2-cyanopropan-2-yl)isoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-ylthio)phenyl)urea;
1-(3-(6, 7-dimethoxyquinazolin-4-ylthio)phenyl)-3-(3-(trifluoromethyl)isoxazol-5-yl)urea;
1-(3-(7-ethoxy-6-methoxyquinazolin-4-yloxy)phenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;
1-(5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl)-3-(3-(7-ethoxy-6-methoxyquinazolin-4-yloxy)phenyl)urea;
1-(5-(1, 3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl)-3-(3-(7-ethoxy-6-methoxyquinazolin-4-ylthio)phenyl)urea;
1-(3-(7-ethoxy-6-methoxyquinazolin-4-ylthio)phenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;
1-(3-(6-ethoxy-7-methoxyquinazolin-4-yloxy)phenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;
1-(5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl)-3-(3-(6-ethoxy-7-methoxyquinazolin-4-yloxy)phenyl)urea·
1-(3-(6-ethoxy-7-methoxyquinazolin-4-ylthio)phenyl)-3-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)urea;

1-(5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl)-3-(3-(6-ethoxy-7-methoxyquinazolin-4-ylthio)phenyl)urea;

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 2;

each R^1 is independently $-R^6OR^7$ or $-R^6OR^9OR^7$;

each R^6 is independently a direct bond, alkylene chain or alkenylene chain;

each R^7 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaralkyl, and

each R^9 is independently an alkylene chain or an alkenylene chain.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is O.

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is S.

10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{10} is selected from hydrogen, halo, alkyl, cyanoalkyl, haloalkyl or cycloalkyl.

11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein R^{10} is alkyl or haloalkyl.


12. The compound of any of claim 11, or a pharmaceutically acceptable salt thereof, wherein R^{10} is C_4 alkyl or C_4 haloalkyl.

13. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^{10} is $-C(CH_3)_3$, $-CH(CH_3)_2$, $-C(CH_3)_2CN$, $-C(CH_3)_2CF_3$, $-CF(CH_3)_2$, $-CF_2(CH_3)$, $-C(CH_3)_2CH_2OH$, $-C(CH_3)(CH_2F)_2$, $-C(CH_3)_2CH_2OCH_3$, or CF_3.

14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, where n is 2 and each R^{1a} and R^{1b} are independently selected from methoxy and methoxyethoxy; or


R^{1a} and R^{1b} together with the carbon atoms on which they are substituted form an ethylenedioxy group.

15. A compound which is




or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition, comprising from about 1 mg to about 2000 mg of a compound that is




or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or diluent.

17. (New) A pharmaceutical composition according to claim 16, comprising from about 10 mg to about 1000 mg of a compound that is




or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition according to claim 16, comprising from about 20 mg to about 500 mg of a compound that is



or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition according to claim 16, comprising from about 25 mg to about 250 mg of a compound that is



or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition according to claim 16, wherein said pharmaceutical composition is in a dosage form suitable for oral administration to a patient.

21. A pharmaceutical composition according to claim 20, wherein said dosage form is a tablet, capsule, troche, lozenge, pastille, cachet, pellet, gum, bulk powder, effervescent powder, non-effervescent powder, solution, emulsion, suspension, wafer, sprinkle, elixir, or syrup.

22. A pharmaceutical composition according to claim 21 wherein said dosage form is a tablet, capsule, cachet, effervescent powder, non-effervescent powder, solution, emulsion, suspension, or syrup.

23. A pharmaceutical composition according to claim 22, wherein said dosage form is a tablet, capsule, solution, emulsion, suspension, or syrup.

24. A pharmaceutical composition according to claim 22, wherein said dosage form is a tablet or capsule.

25. A pharmaceutical composition according to claim 22, wherein said dosage form is a tablet.